Login Register Cart 0
Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Commentary

Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges

Author(s): Joab Williamson*, Alexander Spicer and Pierre-Albert Colcomb

Volume 10, 2024

Published on: 02 September, 2024

Article ID: e26673371318424 Pages: 5

DOI: 10.2174/0126673371318424240813063046

TIMBC 2025
Abstract

Cell and gene therapy, offering unprecedented solutions for complex diseases, have attracted significant attention in both the scientific and financial communities. This article explores the tumultuous financial journey of companies specializing in these advanced therapeutic modalities. The discussion illuminates the volatility of share prices, challenges in valuation, and complexities in fundraising while delving into the inherent risks of the cell and gene therapy development pathway. Through an examination of various strategies, the article underscores the importance of diverse investment sources, robust collaborations, risk-sharing models, and portfolio diversification in ensuring financial stability. As the field burgeons, understanding these financial dynamics is paramount for stakeholders aiming to harness the transformative potential of cell and gene therapies.

Keywords: Financial stability, biotech industry, gene therapy development, investment strategies, clinical trials, monoclonal antibodies.

[1]
Gonçalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo) 2017; 15(3): 369-75.
[http://dx.doi.org/10.1590/s1679-45082017rb4024] [PMID: 29091160]
[2]
Aspden P. The costs and benefits of medical innovation. US: National Academies Press 2002.
[3]
Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020; 27(1): 1-30.
[http://dx.doi.org/10.1186/s12929-019-0592-z] [PMID: 31894001]
[4]
Ahluwalia G. Available from: https://www.bdo.co.uk/en-gb/insights/industries/life-sciences/cell-and-gene-therapy-investing-in-a-new-tomorrow(Accessed on: 29 Dec 2023)
[5]
High-dose AAV gene therapy deaths. Nat Biotechnol 2020; 38(8): 910.
[http://dx.doi.org/10.1038/s41587-020-0642-9] [PMID: 32760031]
[6]
Moody J, Milligan WD, St Onge M, Goonewardene A, Rivers P. Cell and gene therapy: A snapshot of investor perspectives. Cytotherapy 2021; 23(3): 256-60.
[http://dx.doi.org/10.1016/j.jcyt.2020.11.005] [PMID: 33281066]
[7]
Norviel V, Hoffmeister D, Ravitz G, Ravitz J. a preliminary evaluation of the RMAT designation's effect on publicly traded company stock price Available from: https://www.wsgr.com/en/insights/a-preliminary-evaluation-of-the-rmat-designations-effect-on-publicly-traded-company-stock-price.html(Accessed on: 29 Dec 2023)
[8]
Ohba M, Falkner R. Innovative capabilities and strategic alliances: Who is gaining what in the pharmaceutical industry? J Commer Biotechnol 2007; 13(4): 273-82.
[http://dx.doi.org/10.1057/palgrave.jcb.3050053]
[9]
Parrish M. Pharma’s damaged reputation. Available from: https://www.pharmamanufacturing.com/sector/small-molecule/article/11303099/pharmas-damaged-reputation(Accessed on: 29 Dec 2023)
[10]
Neil J. Important aspects of drug development. Available from: https://proventainternational.com/the-challenges-of-cmc-in-cell-and-gene-therapies/(Accessed on: 29 Dec 2023)
[11]
Management Sciences for Health. Pharmaceutical Financing Strategies 2012. Available from: https://msh.org/wp-content/uploads/2013/04/mds3-ch11-financing-strategies-mar2012.pdf(Accessed on: 29 Dec 2023)
[12]
Holian M, Whitney M, Gilbert A. How To navigate pharma collaboration and licensing agreements. Available from: https://www.lifescienceleader.com/doc/how-to-navigate-pharma-collaboration-and-licensing-agreements-0001(Accessed on: 29 Dec 2023)
[13]
Ciulu R. Diversification strategy in the pharmaceutical industry. SSRN Electron J 2008; 2008; 1283129.
[http://dx.doi.org/10.2139/ssrn.1283129]
[14]
Firica C. Financial strategies and their impact on pharma companies’ budgets Available from: https://www.linkedin.com/pulse/financial-strategies-impact-pharma-companies-budgets-firica-mba/(Accessed on: 29 Dec 2023)
[15]
Zhu J. Key Considerations for your life sciences IP strategy. Available from: https://www.foxrothschild.com/publications/key-considerations-for-your-life-sciences-ip-strategy(Accessed on: 29 Dec 2023)
[16]
European commission. intellectual property. Available from: trade.ec.europa.eu (Accessed on: 29 Dec 2023). Available from:https://trade.ec.europa.eu/access-to-markets/en/content/intellectual-property(Accessed on: 29 Dec 2023)
[17]
Robinson S. Chemistry, Manufscturing and controls (CMC), GARDP. Available from: https://revive.gardp.org/resource/chemistry-manufacturing-and-controls-cmc/?cf=encyclopaedia(Accessed on: 29 Dec 2023)

Rights & Permissions Print Cite
Article Metrics
10
1
Wayfinder Image
TIMBC 2025
© 2025 Bentham Science Publishers | Privacy Policy